studies

metastatic/advanced - colorectal cancer (mCRC), atezolizumab plus cometinib vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMblaze-370 (AC ; all population), 2019 1.00 [0.73; 1.37] 1.00[0.73; 1.37]IMblaze-370 (AC ; all population), 201910%273NAnot evaluable progression or deaths (PFS)detailed resultsIMblaze-370 (AC ; all population), 2019 1.25 [0.94; 1.66] 1.25[0.94; 1.66]IMblaze-370 (AC ; all population), 201910%273NAnot evaluable objective responses (ORR)detailed resultsIMblaze-370 (AC ; all population), 2019 1.24 [0.24; 6.50] 1.24[0.24; 6.50]IMblaze-370 (AC ; all population), 201910%273NAnot evaluable AE (any grade)detailed resultsIMblaze-370 (AC ; all population), 2019 1.52 [0.42; 5.53] 1.52[0.42; 5.53]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.15 [0.67; 1.97] 1.15[0.67; 1.97]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable AE leading to death (grade 5)detailed resultsIMblaze-370 (AC ; all population), 2019 1.12 [0.21; 5.90] 1.12[0.21; 5.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMblaze-370 (AC ; all population), 2019 2.72 [1.15; 6.39] 2.72[1.15; 6.39]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable SAE (any grade)detailed resultsIMblaze-370 (AC ; all population), 2019 2.26 [1.24; 4.14] 2.26[1.24; 4.14]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable STRAE (any grade)detailed resultsIMblaze-370 (AC ; all population), 2019 2.73 [1.26; 5.89] 2.73[1.26; 5.89]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable TRAE (any grade)detailed resultsIMblaze-370 (AC ; all population), 2019 0.74 [0.19; 2.79] 0.74[0.19; 2.79]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable TRAE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.85 [0.50; 1.44] 0.85[0.50; 1.44]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99] 0.89[0.08; 9.99]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99] 0.89[0.08; 9.99]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.81 [0.20; 16.42] 1.81[0.20; 16.42]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.29 [0.05; 1.77] 0.29[0.05; 1.77]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 2.31 [0.49; 10.78] 2.31[0.49; 10.78]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.22[0.01; 6.66]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 3.22 [0.39; 26.58] 3.22[0.39; 26.58]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.80[0.08; 40.29]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Cough AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19] 0.44[0.06; 3.19]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Dermatitis acneiform AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.80[0.08; 40.29]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.89 [0.68; 5.22] 1.89[0.68; 5.22]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Dysphonia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.49 [0.17; 1.40] 0.49[0.17; 1.40]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Guillain-Barré syndrome AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Headache AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.08 [0.02; 0.37] 0.08[0.02; 0.37]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.22[0.01; 6.66]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.80[0.08; 40.29]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Intestinal perforation AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.22[0.01; 6.66]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.80[0.08; 40.29]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.22[0.01; 6.66]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.80[0.08; 40.29]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.02 [0.00; 0.39] 0.02[0.00; 0.39]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66] 0.22[0.01; 6.66]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29] 1.80[0.08; 40.29]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Pneumonitis AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 6.47 [0.36; 115.44] 6.47[0.36; 115.44]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Rash AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 1.59 [0.32; 7.82] 1.59[0.32; 7.82]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.44 [0.03; 7.19] 0.44[0.03; 7.19]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19] 0.44[0.06; 3.19]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Thrombocytopenia AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90] 0.89[0.03; 26.90]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable Weight decreased AE (grade 3-4)detailed resultsIMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65] 0.45[0.01; 22.65]IMblaze-370 (AC ; all population), 201910%259NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-05-20 19:42 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 183,137,138 - treatments: 696

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons